证券日报网讯 11月25日晚间，科森科技发布公告称，昆山科森科技股份有限公司（以下简称"公司"） 拟在马来西亚设立境外全资子公司森创力精密工业（马来西亚）私人有限公司（暂定名，最终以实际注 册登记为准），以从事精密金属结构件的研发、生产与销售等相关业务；投资金额：拟投资金额为3， 000万美元，实际投资金额以中国及当地主管部门批准金额为准。 （编辑 楚丽君） ...

证券日报网讯11月25日晚间，科森科技（603626）发布公告称，公司董事会同意聘任王亚倩女士为董事 会秘书。 ...

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

每经头条（nbdtoutiao）——688496，被证监会立案！刚上市业绩就变脸，亏损超1亿元；核心产品受重 创：第一大客户"自产自用"，减少采购 截至发稿，科森科技市值为66亿元。 （记者 曾健辉） 每经AI快讯，科森科技（SH 603626，收盘价：11.85元）11月25日晚间发布公告称，公司第四届第二十 三次董事会会议于2025年11月25日以现场结合通讯方式召开。会议审议了《关于聘任董事会秘书的议 案》等文件。 2024年1至12月份，科森科技的营业收入构成为：手机及平板电脑结构件占比76.75%，新能源-储能业务 占比10.58%，医疗手术器械结构件占比8.1%，一般精密金属结构件占比3.33%，其他业务占比1.23%。 ...

Group 1 - The company announced the appointment of Wang Yaqian as the secretary of the board, with a term aligned with the fourth board's tenure [1] - For the first three quarters of 2025, the company reported a revenue of 2.453 billion yuan and a net profit attributable to shareholders of -115 million yuan [1]

11月25日晚间科森科技（603626）公告，因业务发展需要，公司拟在马来西亚投资新建生产基地，满足 境外客户的订单需求。 该公司消费电子产品包括智能手机、笔记本电脑、平板电脑、智能穿戴、智能音箱、加热不燃烧电子烟 结构件、VR等终端产品的外壳、中框、中板、按键、标志、转轴（铰链）组装等；医疗器械产品包括 手术刀、骨钉、心脏起搏器等终端产品所需结构件；储能产品主要为PACK模组产品等。 2025年前三季度，科森科技业绩延续亏损，期内实现营业收入24.53亿元，同比下滑6.45%；归母净利润 亏损1.15亿元，同比增长50.94%。 对于业绩亏损原因，该公司在2025年半年报中曾阐述，部分新产品处于量产爬坡阶段，产品毛利不及预 期；为突破技术瓶颈，争取更多的市场订单，公司研发费用保持较高投入。 该公司以全资子公司科森科技（新加坡）有限公司（下称"新加坡科森"）作为路径公司，在马来西亚柔 佛州设立森创力精密工业（马来西亚）私人有限公司（暂定名，最终以实际注册登记为准，下称"马来 西亚公司"）。公司本次拟投资金额为3000万美元，实际投资金额以中国及当地主管部门批准金额为 准。 据披露，马来西亚公司经营范围包括精密 ...

Core Viewpoint - Kosen Technology (603626.SH) plans to invest in a new production base in Malaysia to meet the order demands of overseas customers, with an investment amount of $30 million [1] Group 1: Investment Details - The investment will be executed through Kosen Technology (Singapore) Co., Ltd., a wholly-owned subsidiary [1] - The new company in Malaysia will be named Sen Chuang Li Precision Industry (Malaysia) Private Limited, pending final registration [1] - The investment amount is set at $30 million [1] Group 2: Strategic Purpose - The establishment of the new production base aims to satisfy the growing order requirements from international clients [1]

证券代码：603626 证券简称：科森科技 公告编号：2025-052 昆山科森科技股份有限公司 关于对外投资的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：昆山科森科技股份有限公司（以下简称"公司"）拟在马 来西亚设立境外全资子公司森创力精密工业（马来西亚）私人有限公司（暂定名， 最终以实际注册登记为准），以从事精密金属结构件的研发、生产与销售等相关 业务； 投资金额：拟投资金额为 3,000 万美元，实际投资金额以中国及当地主 管部门批准金额为准； 相关风险提示：本次对外投资须履行国内境外投资备案或审批手续以及 马来西亚当地投资许可和企业登记等审批程序，尽管目前评估不存在重大法律障 碍，但依然存在不能获得相关主管部门批准的风险，本次对外投资能否顺利实施 存在一定的不确定性；马来西亚的法律法规、政策体系、商业环境、文化特征等 与国内存在较大差异，在马来西亚投资设立公司及运营管理过程中，存在一定的 管理、运营和市场风险，本次对外投资效果能否达到预期存在不确定性。 一、对外投资概述 （一）对 ...

昆山科森科技股份有限公司 关于聘任董事会秘书的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆山科森科技股份有限公司（以下简称"公司"）于2025年11月25日召开了 第四届董事会第二十三次会议，审议通过了《关于聘任董事会秘书的议案》，公 司董事会同意聘任王亚倩女士（个人简历详见附件）为董事会秘书，任职期限与 公司第四届董事会任期一致。 证券代码：603626 证券简称：科森科技 公告编号：2025-051 电子邮箱：ksgf@ kersentech.com 特此公告。 昆山科森科技股份有限公司 董事会 2025 年 11 月 26 日 附：简历 王亚倩女士具备担任董事会秘书所需的专业知识，已取得上海证券交易所颁 发的《董事会秘书资格证明》，任职资格符合《中华人民共和国公司法》、《上海 证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》和《公司章程》等有关规定。 王亚倩女士联系方式： 联系地址：江苏省昆山市开发区新星南路 155 号 联系电话：0512- 36688666 传真：0 ...

证券代码：603626 证券简称：科森科技 公告编号：2025-050 昆山科森科技股份有限公司 第四届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）昆山科森科技股份有限公司（以下简称"公司"）第四届董事会第二十 三次会议（以下简称"本次会议"）于2025年11月25日以现场结合通讯方式召开， 会议由董事长徐金根先生主持。 （四）本次会议的召集、召开符合《公司法》及《公司章程》的有关规定， 会议决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： （一）审议通过《关于聘任董事会秘书的议案》 表决结果：同意 7 票；反对 0 票；弃权 0 票。 该议案已经公司第四届董事会提名委员会第五次会议审议并通过。 具体内容详见公司同日披露于《上海证券报》、《中国证券报》、《证券时报》 和上海证券交易所网站（www.sse.com.cn）的《关于聘任董事会秘书的公告》。 （二）审议通过《关于对外投资的议案》 表决结果：同意 7 票；反对 0 票；弃权 0 票。 （ ...